These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 2795096)
1. Generation of tumoricidal effector cells by human C-reactive protein and muramyl tripeptide: a comparative study. Gautam S; Deodhar S J Biol Response Mod; 1989 Oct; 8(5):560-9. PubMed ID: 2795096 [TBL] [Abstract][Full Text] [Related]
2. Macrophage activation and generation of tumoricidal activity by liposome-associated human C-reactive protein. Barna BP; Deodhar SD; Gautam S; Yen-Lieberman B; Roberts D Cancer Res; 1984 Jan; 44(1):305-10. PubMed ID: 6690042 [TBL] [Abstract][Full Text] [Related]
3. Use of resealed erythrocytes as delivery system for C-reactive protein (CRP) to generate macrophage-mediated tumoricidal activity. Gautam S; Barna B; Chiang T; Pettay J; Deodhar S J Biol Response Mod; 1987 Jun; 6(3):346-54. PubMed ID: 3598603 [TBL] [Abstract][Full Text] [Related]
4. Augmentation of NK cell activity in tissue specific sites by liposomes incorporating MTP-PE. Talmadge JE; Schneider M; Collins M; Phillips H; Herberman RB; Wiltrout RH J Immunol; 1985 Aug; 135(2):1477-83. PubMed ID: 4008928 [TBL] [Abstract][Full Text] [Related]
5. Isolation of tumoricidal macrophages from lung melanoma metastases of mice treated systemically with liposomes containing a lipophilic derivative of muramyl dipeptide. Key ME; Talmadge JE; Fogler WE; Bucana C; Fidler IJ J Natl Cancer Inst; 1982 Nov; 69(5):1198-98. PubMed ID: 6957661 [TBL] [Abstract][Full Text] [Related]
6. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity. Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715 [TBL] [Abstract][Full Text] [Related]
7. Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide. Schroit AJ; Fidler IJ Cancer Res; 1982 Jan; 42(1):161-7. PubMed ID: 7053846 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of lung metastases in mice bearing a malignant fibrosarcoma by treatment with liposomes containing human C-reactive protein. Deodhar SD; James K; Chiang T; Edinger M; Barna BP Cancer Res; 1982 Dec; 42(12):5084-8. PubMed ID: 7139613 [TBL] [Abstract][Full Text] [Related]
9. Potentiating effect of muramyl dipeptide and its lipophilic analog encapsulated in liposomes on tumor cell killing by human monocytes. Sone S; Mutsuura S; Ogawara M; Tsubura E J Immunol; 1984 Apr; 132(4):2105-10. PubMed ID: 6699409 [TBL] [Abstract][Full Text] [Related]
10. In situ activation of mouse lung macrophages by coadministration of liposomes containing the lipopeptide CGP 31362 and interleukin 2 involves interaction with T lymphocytes and natural killer cells. Utsugi T; Dinney CP; Killion JJ; Brown D; Fidler IJ Lymphokine Cytokine Res; 1991 Dec; 10(6):487-93. PubMed ID: 1804312 [TBL] [Abstract][Full Text] [Related]
11. Induction of murine macrophage tumoricidal activity and treatment of experimental pulmonary metastases by liposomes containing lipophilic muramyl dipeptide analogs. Phillips NC; Chedid L; Bernard JM; Level M; Lefrancier P J Biol Response Mod; 1987 Dec; 6(6):678-91. PubMed ID: 3450784 [TBL] [Abstract][Full Text] [Related]
12. The role of anti-asialo GM1 antibody-sensitive cells in the implementation of tumor-specific T cell-mediated immunity in vivo. Yoshioka T; Sato S; Fujiwara H; Hamaoka T Jpn J Cancer Res; 1986 Aug; 77(8):825-32. PubMed ID: 3093429 [TBL] [Abstract][Full Text] [Related]
13. Synergism between lymphokines and muramyl dipeptide encapsulated in liposomes: in situ activation of macrophages and therapy of spontaneous cancer metastases. Fidler IJ; Schroit AJ J Immunol; 1984 Jul; 133(1):515-8. PubMed ID: 6373933 [TBL] [Abstract][Full Text] [Related]
14. Inability of anti-asialo-GM1 and 2-chloroadenosine to abrogate maleic anhydride-divinyl ether-induced resistance against experimental murine lung carcinoma metastases. Schultz RM; Tang JC; DeLong DC; Ades EW; Altom MG Cancer Res; 1986 Nov; 46(11):5624-8. PubMed ID: 3756909 [TBL] [Abstract][Full Text] [Related]
15. Effect of rabbit anti-asialo GM1 treatment in vivo or with anti-asialo GM1 plus complement in vitro on cytotoxic T cell activities. Stitz L; Baenziger J; Pircher H; Hengartner H; Zinkernagel RM J Immunol; 1986 Jun; 136(12):4674-80. PubMed ID: 3486908 [TBL] [Abstract][Full Text] [Related]
16. Human alveolar macrophages: potentiation of their tumoricidal activity by liposome-encapsulated muramyl dipeptide. Sone S; Tsubura E J Immunol; 1982 Sep; 129(3):1313-7. PubMed ID: 7108208 [TBL] [Abstract][Full Text] [Related]
17. Induction of nitric oxide production and tumoricidal properties in murine macrophages by a new synthetic lipopeptide JBT3002 encapsulated in liposomes. Eue I; Kumar R; Dong Z; Killion JJ; Fidler IJ J Immunother; 1998 Sep; 21(5):340-51. PubMed ID: 9789196 [TBL] [Abstract][Full Text] [Related]
18. Liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) promotes haemopoietic recovery in irradiated mouse. Fedorocko P Int J Radiat Biol; 1994 Apr; 65(4):465-75. PubMed ID: 7908934 [TBL] [Abstract][Full Text] [Related]
19. Cytotoxic T-cell-mediated antitumor effect of levamisole against murine syngeneic fibrosarcoma. Gomi K; Morimoto M; Nomoto K Cancer Res; 1982 Oct; 42(10):4197-202. PubMed ID: 6980702 [TBL] [Abstract][Full Text] [Related]
20. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. Kleinerman ES; Erickson KL; Schroit AJ; Fogler WE; Fidler IJ Cancer Res; 1983 May; 43(5):2010-4. PubMed ID: 6831430 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]